Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Remote home-based eCTG fetal heart monitoring for complicated pregnancies

Official title: Remote Electrophysiological Cardiotocography (eCTG), Evaluation of Feasibility in (a Selected Group of) Complicated Pregnancies From 32 Until 37 Weeks Gestational Age in a Home@Hospital Setting: a Prospective Cohort Study

Run by Maxima Medical Center · NCT06859177 · Data updated 2026-11-12

This project tests whether people with complicated pregnancies can self-use a non-invasive fetal ECG (eCTG) device at home or in-hospital to monitor their baby's heart and their own vitals.

More Pregnancy Related trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment60 (estimated)
SponsorMaxima Medical Center
Academic / other
Locations1 site (Veldhoven, North Brabant)
StatusRecruiting
StartedMarch 25, 2025
Main results expectedJune 2026
Study endsDecember 2026
Registry record updatedSeptember 26, 2025
Trial IDNCT06859177 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults (≥18 years) with a singleton pregnancy at 32+0–36+6 weeks who require fetal monitoring at least twice weekly for conditions like pre-eclampsia, fetal growth restriction, or PPROM and who can provide informed consent and use a smartphone.

Probably not a fit

Patients needing intravenous medication, with very high blood pressure (>160/110 mmHg), absent or reversed umbilical artery flow, HELLP syndrome, or those expected to need obstetric intervention within 48 hours are unlikely to benefit and should remain in-hospital.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional cohort will enroll pregnant participants (32+0 to 36+6 weeks, singleton) who require frequent fetal monitoring and ask them to self-administer a non-invasive fetal ECG (eCTG) recording daily during admission or at least twice weekly as outpatients. Participants will also measure blood pressure, heart rate and temperature, enter measurements and symptoms into a smartphone app, and complete three questionnaires about wellbeing and satisfaction. The primary outcome is the success rate of self-administered eCTG measurements, while secondary outcomes include maternal and perinatal outcomes, patient and healthcare professional satisfaction, and antenatal cost analysis. Data collection and monitoring will take place at a single site with technical collaboration from Eindhoven University of Technology.

Why it matters

Potential benefit: If successful, this approach could enable safe remote monitoring that reduces in-person visits and gives patients more control while maintaining fetal surveillance.

How similar studies have gone: Small feasibility and pilot programs of home CTG and other non-invasive fetal monitoring technologies have shown promise, but home eCTG monitoring remains relatively novel and not yet widely validated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

* Minimum age of 18 years old
* Pregnant patients with a gestational age between 32+0 and 36+6 weeks and days
* Singleton pregnancy
* Any indication for fetal monitoring at least twice per week (e.g.):

  * Pre-eclampsia (PE)
  * Fetal growth restriction (FGR)
  * Preterm pre-labor rupture of membranes (PPROM)
* Absence of exclusion criteria \> 24 hours after admission.
* Oral and written informed consent is obtained.

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

* An indication for intravenous medication
* Blood pressure \>160/110 A millimeter of mercury (mmHg)
* Absent-/or reversed flow umbilical artery Doppler
* Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) (Table 1)
* Obstetric intervention expected \<48 hours, e.g. due to:

  * Non reassuring cardiotocography (CTG)
  * Active vaginal blood loss
  * Signs of abruption placentae
  * Meconium stained amniotic fluid
  * Signs of chorioamnionitis
* Patients admitted with a clinical diagnosis of sepsis with hypotension (i.e. septic shock).
* Insufficient knowledge of Dutch or English language
* Insufficient comprehension of instruction Nemo Remote® or patient information
* Fetal and/or maternal cardiac arrhythmias
* Contraindications to abdominal patch placement (dermatologic diseases of the abdomen precluding preparation of the abdomen with abrasive paper)
* Patients connected to an external or implanted electrical stimulator, such as Transcutaneous Electro Neuro Stimulation (TENS) and pacemaker (because of disturbance of the electrophysiological signal).

Where it's running

  • Maxima Medical Center
    Veldhoven, North Brabant, Netherlands
    Recruiting

Study contacts

  • Principal investigator: Judith O.E.H. van Laar, MD, PhD — Máxima Medical Center, Technical University of Eindhoven
  • Study coordinator: Sofie van Weelden, MSc
  • Email: s.vanweelden@mmc.nl
  • Phone: +31408888384

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.